Considerations for the pharmacological treatment of diabetes in older adults

Diabetes Spectrum

Volumn 20, Issue 4, 2007, Pages 239-247

  Odegard, Peggy Soule ^a   Setter, Stephen M ^b   Neumiller, Joshua J ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA;

AGING; B LYMPHOCYTE; BLOOD GLUCOSE MONITORING; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; EDEMA; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESPONSE; KIDNEY CLEARANCE; KIDNEY DISEASE; LIVER CLEARANCE; MEDICAL DECISION MAKING; MONOTHERAPY; NEUROPATHY; ONSET AGE; OUTCOME ASSESSMENT; PATIENT CARE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; RETINOPATHY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; STOMACH EMPTYING; TREATMENT INDICATION; WEIGHT GAIN;

EID: 36749077665     PISSN: 10409165     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaspect.20.4.239     Document Type: Review

References (42)

1. Centers for Disease Control and Prevention: National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005. Atlanta, Ga., U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2005
2. Meneilly GS, Elahi D, Minaker KL, Sclater AL, Rowe JW: Impairment of noninsulin-mediated glucose disposal in the elderly. J Clin Endocrinol Metab 68:566-571, 1989
3. Forbes A, Elliott T, Tildesley H, Finegood D, Meneilly GS: Alterations in non-insulin mediated glucose uptake in the elderly patient with diabetes. Diabetes 47:1915-1919, 1998
4. Bourey RE, Kohrt WM, Kirwan JP, Statin MA, King DS, Holloszy JO: Relationship between glucose tolerance and glucose-stimulated insulin response in 65 year-olds. J Gerontol 48:M122-M127, 1993
5. Change AM, Halter JB: Aging and insulin secretion. Am J Physiol Endocrinol Metab 284:E7-E12, 2003
6. Singh I, Marshall MC Jr: Diabetes mellitus in the elderly. Endocrinol Metab Clin North Am 24:255-272, 1995
7. Meneilly GS, Cheung E, Tuokko H: Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 43:403-410, 1994
8. Mangoni AA, Jackson HD: Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 57:6-14, 2003
9. McLean AJ, LeCouteur DG: Aging biology and geriatrics clinical pharmacology. Pharm Rev 56:163-184, 2004
10. Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM: Pharmacotherapy: A Pathophysiologic Approach. 6th ed. Stamford, Conn., Appleton & Lange, 2005
11. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
12. California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes: Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatrics Soc 51:S265-S280, 2003
13. American Diabetes Association: Standards of medical care in diabetes (Position Statement). Diabetes Care 30 (Suppl. 1):S4-S41, 2007
14. Durso SC: Using clinical guidelines designed for older adults with diabetes mellitus and complex health status. JAMA 295:1935-1940, 2006
15. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 29:1963-1972, 2006
16. Omnicare, Inc.: Geriatric Pharmaceutical Care Guidelines. 2007 ed. Covington, Ky., Omnicare, Inc., 2007
17. The DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
18. U.K. Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-853, 1998
19. Action to Control Cardiovascular Risk in Diabetes (ACCORD). Available online from http://www.accordtrial.org/public/index.cfm. Accessed 20 June 2007
20. Curb JD, Presset SI, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 276:1886-1892, 1996
21. Pyorala K, Pedersen TR, Kjekshus J, Faergaman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20:614-620, 1997
22. Cryer PE, Davis SN, Shamoon H: Hypoglycemia in diabetes. Diabetes Care 26:1902-1912, 2003
23. Ramlo-Halsted BA, Edelman SV: The natural history of type 2 diabetes: practical points to consider in developing prevention and treatment strategies. Clin Diabetes 18:80-85, 2000
24. Janka HU, Plewe G, Busch K: Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc 55:182-188, 2007
25. Yki-Jarvinen H, Dressier A, Ziemen M: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 23:1130-1136, 2000
26. Riddle MC, Rosenstock J, Gerich J: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080-3086, 2003
27. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH: Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a U.S. consensus panel of experts. Arch Intern Med 163:16-24, 2003
28. American Medical Directors Association: Managing Diabetes in the Long-Term Care Setting. Columbia, Md., American Medical Directors Association, 2002
29. Omnicare, Inc.: Geriatric Pharmaceutical Care Guidelines: Diabetes Mellitus. 2007 ed. Covington, Ky., Omnicare, Inc., 2007, p. 231-251
30. Shorr RI, Ray WA, Daugherty JR, Griffin MR: Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 44:751-755, 1996
31. Brodows RG: Benefits and risks with glyburide and glipizide in elderly NIDDM patients. Diabetes Care 15:75-80, 1992
32. Del Prato S, Heine RJ, Keilson L, Guitard C, Shen SG, Emmons RP: Treatment of patients over 64 years of age with type 2 diabetes. Diabetes Care 26:2075-2080, 2003
33. Choudhury S, Hirschberg Y, Filipek R, Lasseter K, McLeod JF: Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis. J Clin Pharmcol 40:634-640, 2000
34. Zarowitz BJ, Tangalos EG, Hollenack K, O'Shea T: The application of evidence-based principles of care in older persons (issue 3): management of diabetes mellitus. J Am Med Dir Assoc 7:234-240, 2006
35. Pfizer, Inc.: Exubera product information, 2007. Available online from http://www.exuberaprofessional.com
36. Linnebjerg H, Kothare PA, Park S, Mace K, Reddy S, Mitchell M, Lins R: Effect of renal impairment on the pharmacokinetics of exenatide [article online]. J Clin Pharmacol. Available online from http://www.blackwell- synergy.com/doi/abs/10.1111/j.1365-2125.2007.02890.x
37. Deacon CF: Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opin Invest Drugs 16:533-545, 2007
38. Kleppinger EL, Vivian EM: Pramlintide for the treatment of diabetes mellitus. Ann Pharmacother 37:1082-1089, 2003
39. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care 26:784-790, 2003
40. Kirplchnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Intern Med 137:25-33, 2002
41. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108:2941-2948, 2003
42. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471, 2007